Wei Zhou

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States

Are you Wei Zhou?

Claim your profile

Publications (1)2.73 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nilotinib (AMN-107, Tasigna) is a small-molecule inhibitor of BCR/ABL, approved for chronic myelogenous leukemia. We developed and validated, according to FDA-guidelines, an LC-MS assay for sensitive, accurate and precise quantitation of nilotinib in 0.2 mL human plasma or serum. After acetonitrile protein precipitation, separation is achieved with a hydro-Synergi column and a 0.1% formic acid in methanol/water-gradient. Detection uses electrospray, positive-mode ionization mass spectrometry. Between 5 (LLOQ) and 5000 ng/mL, accuracy (92.1-109.5%), intra-assay precision (2.5-7.8%), and inter-assay precision (0-5.6%)) were within FDA limits. We demonstrated the suitability of this assay by quantitating plasma concentrations of nilotinib in a healthy volunteer after oral administration of 400 mg nilotinib.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 08/2009; 877(20-21):1894-900. DOI:10.1016/j.jchromb.2009.05.034 · 2.73 Impact Factor